Investors Can Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit

Attention Edwards Lifesciences Corporation (NYSE: EW) investors! If you purchased securities from February 6, 2024, to July 24, 2024, you could be eligible for compensation. The deadline to join the class action lawsuit is December 13, 2024.

Here’s the deal: Rosen Law Firm, a respected global investor rights law firm, is leading the charge on this case. They have already filed a class action lawsuit on behalf of investors who suffered damages due to alleged securities fraud by Edwards Lifesciences Corporation.

During the Class Period, Edwards’ executives made statements about expected revenue for 2024, specifically regarding their core product, Transcatheter Aortic Valve Replacement (TAVR). They spoke confidently about their ability to capitalize on untreated patients and claimed significant demand in untapped markets. However, when the true details were revealed, investors allegedly suffered losses.

If you want to be part of the Edwards class action lawsuit, you can find more information and submit your details at https://rosenlegal.com/submit-form/?case_id=29704 or contact Phillip Kim, Esq. at 866-767-3653 or email [email protected].

Remember, no class has been certified yet, so it’s essential to act before the December 13, 2024, deadline if you wish to be considered for the lead plaintiff role. Rosen Law Firm has a strong track record in securities class actions and shareholder derivative litigation, so you can trust them to represent your interests effectively.

Stay updated with the latest developments in the case by following The Rosen Law Firm on LinkedIn, Twitter, and Facebook. And as always, be sure to consult your own legal counsel before making any decisions.

In the world of investing, knowing your rights and taking action when necessary is key. Don’t miss out on this opportunity to seek justice if you were affected by potential securities fraud at Edwards Lifesciences Corporation.